CASI Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on CASI Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how CASI Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with CASI Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company that focuses on the development and commercialization of therapies for treating cancer and other unmet medical needs. The company’s major products include EVOMELA (melphalan for injection), an intravenous formulation for the treatment of multiple myeloma, and FOLOTYN (pralatrexate), an inhibitor of dihydrofolate reductase, indicated for treating individuals with relapsed or refractory peripheral T-cell lymphoma (PTCL). These products are primarily used in the treatment of hematological malignancies and are targeted at patients requiring stem cell transplantation or treatment for conditions like multiple myeloma and peripheral T-cell lymphoma. CASI collaborates with partners such as Juventas and BioInvent for product development and commercialization. The company operates its subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Beijing, China.
Headquarters
China
Address
1701-1703, China Central Office Tower 1, Huamao Office Building, No. 81, Jianguo Road, Beijing, 100025
Website
www.casipharmaceuticals.com
Telephone
86 1065618789
No of Employees
214
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CASIF (OTC)
Revenue (2024)
$20.7M
-27.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2023)
XYZ
-16.8%
(2023 vs 2022)
Market Cap*
$4.9M
Net Profit Margin (2024)
XYZ
-61.0%
(2023 vs 2022)
* As of and is in US$
CASI Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| EVOMELA – for Multiple Myeloma | Evomela |
| Zimberelimab | Folotyn |
| FOLOTYN - Pralatrexate injection | Mafalan |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company entered into an agreement to sell its entire business operations of the company in China to Kaixin Pharmaceuticals. |
| 2024 | Contracts/Agreements | In February, the company entered into a partnership with China National Medicines Corporation. |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with Mundipharma International Corporation Limited for the commercialization of FOLOTYN. |
Competitor Comparison
| Key Parameters | CASI Pharmaceuticals Inc | Takeda Pharmaceutical Co Ltd | Biogen Inc | Sichuan Huiyu Pharmaceutical Co Ltd | Shenzhen Chipscreen Biosciences Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | Japan | United States of America | China | China |
| City | Beijing | Chuo-Ku | Cambridge | Neijiang | Shenzhen |
| State/Province | Beijing | Tokyo | Massachusetts | Sichuan | Guangdong |
| No. of Employees | 214 | 47,455 | 7,500 | 1,366 | 1,002 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wei-Wu He, Ph.D. | Chairman | Executive Board | 2019 | 61 |
| Chunhua Wang | Chief Operating Officer | Senior Management | 2017 | 54 |
| Hai Huang | Chief Commercial Officer; General Manager - CASI China | Senior Management | 2024 | 57 |
| Jim Goldschmidt | Chief Business Development Officer | Senior Management | - | - |
| James Huang | Director | Non Executive Board | 2013 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer